95P A phase II study of combination of H101 (a recombinant human adenovirus type 5) and nivolumab for advanced hepatocellular carcinoma (HCC) after systemic therapy failure
Author:
J. Xie,L. Yi,Z. Meng
Publication:
Immuno-Oncology Technology
Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd.